Engineered heart muscle (EHM) patches are three-dimensional constructs of human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) combined with stromal/fibroblast cells and a supporting scaffold (typically fibrin or collagen hydrogel), designed to be sewn onto the epicardial surface of a failing or infarcted heart to add contractile muscle and remuscularize scarred myocardium.
Engineered heart muscle patches are lab-grown living tissues made from stem cells designed to repair, stabilize, and strengthen damaged hearts.
Human induced pluripotent stem cells are reprogrammed from blood or adult cells—with heart muscle cells (cardiomyocytes), blood vessel cells, and supportive stromal cells.
This tissue engineering approach improves cardiomyocyte retention and engraftment relative to intramyocardial cell injection and carries a lower arrhythmogenic risk.
hiPSC-CMs and stromal cells are embedded in a collagen or fibrin hydrogel and matured under mechanical/dynamic culture conditions to enhance sarcomeric alignment, calcium handling, and force generation.
Modular hexagonal patches are then stacked/assembled into a larger construct (biologic ventricular assist tissue, BioVAT) mounted on a surgical scaffold.
The construct is surgically fixed to the epicardial surface over the region of cardiomyocyte loss during open-chest surgery, sometimes concomitant with CABG.
The graft contributes contractile force to hypocontractile segments, and by thickening the ventricular wall it reduces wall stress, potentially promoting reverse remodeling.
Ventricular wall stress is directly related to the radius impression of the chamber and inversely related to the thickness of the chamber wall (Laplace’s law).
In advanced heart failure, ventricular dilatation and wall thinning amplifier wall, stress, perpetuating, adverse remodeling triggered by activated, cardiac fibroblasts..
Whether benefit derives from true sustained remuscularization with electromechanical coupling versus paracrine effects, like exosome release and passive mechanical support remains debated.
The concept is not a mechanical pump, but a biologically, active contractile layer – and assist tissue rather than assist device. By adding contract on myocardium to a thin ventricular wall therapy may directly augment systolic performance.
Human clinical evidence (BioVAT-HF)
The phase I–II BioVAT-HF trial (Zimmermann et al., NEJM 2026) enrolled patients with symptomatic HFrEF (LVEF ≤35%) refractory to guideline-directed therapy, all under immunosuppression.
The dose-finding portion identified 20 engineered-heart-muscle units as the safe maximal dose.
At the prespecified 3-month interim analysis in patients treated at the maximal dose:
Target heart-wall thickness increased by a mean of ~4.5 mm
LVEF improved by ~3.9 percentage points
Quality of life (KCCQ-OSS) improved by ~6.7 points
Remuscularization was confirmed histologically in an explanted treated heart, providing direct human evidence of engraftment.
On safety, all patients had adverse events; three patients had five episodes of ventricular tachycardia judged unrelated to the graft by epicardial mapping.
The following figure shows the three co-primary efficacy endpoints from the BioVAT-HF trial:
Immunogenicity: Allogeneic hiPSC products require immunosuppression; lifelong immunosuppression is needed if durable remuscularization is the goal, motivating development of gene-edited hypoimmunogenic lines.
Graft maturation and vascularization of clinically sized patches.
Arrhythmia prevention and confirmation of electromechanical integration.
Manufacturing scalability.
These interim results are from a small, open-label, early-phase trial without a randomized comparator for efficacy, so functional benefits should be interpreted cautiously pending the planned phase 3 trial.
Intramyocardial injection of allogeneic hiPSC-CMs (HEAL-CHF trial) — has also shown functional improvement (6-minute walk distance) and represents a parallel line of investigation.
These cells are embedded in a specialized hydrogel or nanofiber framework, such as collagen or gelatin, to form a flexible, beating tissue patch.
Surgeons can graft large patches directly onto the heart surface via open-heart procedures, or use newer foldable, paper-thin designs delivered through small chest incisions.
Recent clinical trials (such as the BioVAT-HF study) have successfully implanted engineered heart muscle (EHM) patches into advanced heart failure patients to stabilize their health while they wait for a full heart transplant.Integration.
Safety: Primate and human studies show that the patches form new blood vessels, integrate electrically with native heart tissue, and improve pumping function without causing dangerous tumors or arrhythmias.